Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma. - Wikidata - wikimedia - TriplyDB

Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma.

Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma.

http://www.wikidata.org/entity/Q54218339

about

Companion diagnostics for the targeted therapy of gastric cancer Complementary utility of targeted next-generation sequencing and immunohistochemistry panels as a screening platform to select targeted therapy for advanced gastric cancer HGF/MET-directed therapeutics in gastroesophageal cancer: a review of clinical and biomarker development.Clinical impact of tumour biology in the management of gastroesophageal cancer Identification of EGFR expression status association with metastatic lymph node density (ND) by expression microarray analysis of advanced gastric cancer.Immunohistochemical analysis of RTKs expression identified HER3 as a prognostic indicator of gastric cancer.Combined HSP90 and kinase inhibitor therapy: Insights from The Cancer Genome Atlas.EGFR gene amplification is relatively common and associates with outcome in intestinal adenocarcinoma of the stomach, gastro-oesophageal junction and distal oesophagus.Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways.Neuropilin-1 is associated with clinicopathology of gastric cancer and contributes to cell proliferation and migration as multifunctional co-receptors.Hypoxia/lncRNA-AK123072/EGFR pathway induced metastasis and invasion in gastric cancer.MET in gastric cancer--discarding a 10% cutoff rule Serum level of hepatocyte growth factor is a novel marker of predicting the outcome and resistance to the treatment with trastuzumab in HER2-positive patients with metastatic gastric cancer.Knockdown of CMTM3 promotes metastasis of gastric cancer via the STAT3/Twist1/EMT signaling pathway.The coexpression and prognostic significance of c-MET, fibroblast growth factor receptor 2, and human epidermal growth factor receptor 2 in resected gastric cancer: a retrospective study.Clinicopathological Significance and Diagnostic Accuracy of c-MET Expression by Immunohistochemistry in Gastric Cancer: A Meta-Analysis.Different clinical significance of FGFR1-4 expression between diffuse-type and intestinal-type gastric cancer.Berberine inhibits EGFR signaling and enhances the antitumor effects of EGFR inhibitors in gastric cancer MET overexpression, gene amplification and relevant clinicopathological features in gastric adenocarcinoma.Therapeutic targeting of fibroblast growth factor receptors in gastric cancer.In situ analysis of FGFR2 mRNA and comparison with FGFR2 gene copy number by dual-color in situ hybridization in a large cohort of gastric cancer patients.MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategy.Update on Gastroesophageal Adenocarcinoma Targeted Therapies.Predictable factors for lymph node metastasis in early gastric cancer analysis of clinicopathologic factors and biological markers.Gene of the month: HGF.Chemotherapy for advanced gastric cancer: future perspective in Japan.The Therapeutic Potential of Targeting the HGF/cMET Axis in Ovarian Cancer.Tumor suppressor microRNA-31 inhibits gastric carcinogenesis by targeting Smad4 and SGPP2.Dynamic tracing for epidermal growth factor receptor mutations in urinary circulating DNA in gastric cancer patients.Comprehensive analyses using next-generation sequencing and immunohistochemistry enable precise treatment in advanced gastric cancer.Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.Novel Targeted Therapies for Esophagogastric Cancer.Clinicopathologic and prognostic significance of human epidermal growth factor receptor in patients with gastric cancer: An updated meta-analysis FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival.Relationship between expression of IGFBP7 and clinicopathological variables in gastric cancer.Assessment and prognostic analysis of EGFR, HER2, and HER3 protein expression in surgically resected gastric adenocarcinomas.Clinical Significance of Glycoprotein Non-metastatic B and Its Association with EGFR/HER2 in Gastrointestinal Cancer.Prognostic relevance of FGFR2 expression in stage II/III gastric cancer with curative resection and S-1 chemotherapy.Targeted therapies for targeted populations: Anti-EGFR treatment for EGFR amplified gastroesophageal adenocarcinoma.A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer.

P2860

Q26780298-535E230E-CE0B-47E9-9EEF-2CCC0F853181 Q33888813-E4F1F33F-AAEA-419C-84D8-AF18F4AA6519 Q33917507-38E9E422-9472-41A9-91F1-EA91C9C8BC19 Q33922534-133E726C-BB03-4EC0-A376-DCC91F8565A1 Q35032328-C3903BF2-ADA6-4BDB-900A-3F9AA3C7E64B Q35051995-4F2EA708-36C7-4E5A-B1BC-4EE1956C19AC Q35930811-DC152D49-578B-4B71-BBB7-5FB09BFE1A9D Q36069955-F401159F-5BA3-4EBC-BB5C-3EE812EE00EB Q36307708-8E00050F-AF65-4808-BB9B-7214820BBB5A Q36489958-9845BB58-3B8F-402D-89B6-987D16160BA6 Q36492594-B80F2A6D-6F4C-4FD7-BF10-4FC26D2CA3E9 Q36554574-DA624B0B-2CED-4C8C-B68E-C0307E97EB44 Q36782629-733E4B80-016E-4008-AC2F-6A214CA2EF62 Q37301868-F871EF36-0390-4DE7-B34B-F927F23BD032 Q37302936-62EB1369-A253-4F58-A6F9-2755FFED45A8 Q37342442-BA2807D6-0D49-49FE-9FCB-D8E76B776D91 Q37567109-98E1ACEE-F917-4833-A863-17D7E0AFDD45 Q37689064-C79257CB-CDC9-408C-AB36-DF87203882F4 Q37705824-5CEC654F-4121-4786-AEB7-0948D92603A7 Q38497265-12F35733-A364-40D3-AD25-36EDED9C2251 Q38602669-C1FEA3DE-2038-4439-90FA-A7CF18560B2E Q38675350-7481ABB0-E232-4E15-9A00-1E6C32201E63 Q38684349-BD62DF04-AA12-4690-AAF8-5AE882017C0E Q38687568-5185ED60-5549-4BE4-9A55-3BD809D6E4FC Q38806819-77B8CF42-7417-4B0F-9BF1-B1DC36920175 Q38815071-091AD289-84D9-4CDD-8B8D-C63CF8C67543 Q38824065-7B9443A1-1378-4737-9F0E-3CEC84A3BE9B Q38825712-9C76D54E-5C2A-4240-9102-90901B3FF05D Q38949788-4029BE74-EF2A-4F37-A80C-010C3B18DF89 Q38951195-C7A56AC4-D572-4777-B356-37A9A213BB4C Q39038837-FCCD0FEA-D5C8-46D5-A27F-606490913836 Q39171565-17129BB4-A444-4317-9CFD-8C72BEDC02C8 Q40332121-5C6250DB-AA7F-42F0-92BF-DBE690453441 Q40733626-1DC68416-8F74-4E69-9FEA-F2D399F3EDFD Q41693807-273EF205-CB7E-4DFD-9764-C4D1DDDE758D Q42717966-1EB65E38-6E93-4C20-9D7C-CCBF0E1616BF Q47552119-1222A9BD-0C98-4FDE-AF62-D75DCFBD46EB Q49639370-522B58EE-CA65-49D1-8C41-5F3171FFEE4A Q49961144-1FADA011-7DF0-4BD9-85CD-F912BD4C4B88 Q52766440-D41E62D9-5D9E-4254-9C9D-1279B3A97D33

P2860

Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma.

http://www.wikidata.org/entity/Q54218339

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

Expression profiles of HER2, E ...... s with gastric adenocarcinoma.

@en

Expression profiles of HER2, E ...... s with gastric adenocarcinoma.

@nl

type

label

Expression profiles of HER2, E ...... s with gastric adenocarcinoma.

@en

Expression profiles of HER2, E ...... s with gastric adenocarcinoma.

@nl

prefLabel

Expression profiles of HER2, E ...... s with gastric adenocarcinoma.

@en

Expression profiles of HER2, E ...... s with gastric adenocarcinoma.

@nl

P1433

Q54218339-1BFF0CCC-979E-4128-9939-1807A5B32C15

P1476

Q54218339-B403DA14-B7F7-4688-A7D9-F90623128804

P2093

Q54218339-266B25E2-08A7-4723-B026-180822BB84F0

Q54218339-4E4BE81B-C046-4B63-95C3-B2B256DFA335

Q54218339-6E166C0A-AB49-4B93-822D-1786ECA9C873

Q54218339-9A0130A7-3E6A-4E21-B8D8-7C3B3B6ABA84

Q54218339-B4D3010E-8B90-4034-B79C-A6A21EF3B059

Q54218339-D3098A62-2E2E-44F6-9D93-EE983ED62A78

P2860

Q54218339-0A977ECA-7F00-4BD6-9405-AEB9DF7DB24E

Q54218339-0ACB1C22-A5D3-43E1-8098-2EEADC2CDDEA

Q54218339-0B55F946-4E4D-4A3A-8119-8BC0370DF923

Q54218339-13B20EDE-DD44-47C9-82EB-60E61116630F

Q54218339-1827BB28-8C7B-42D6-9F93-FCBB62AB5C14

Q54218339-20ACC5F3-933E-4AFD-967C-6B806F3B17E5

Q54218339-38D61E56-64CD-469F-9C41-962CE9F181DD

Q54218339-3C63FE92-5F13-4042-916F-16851F01AD5B

Q54218339-3D4ECA71-A90D-49BC-8D2E-8A3F744C476C

Q54218339-4B7199C8-B34B-4689-944B-611634B12D58

P2888

Q54218339-ACBE8A12-21E8-4984-AACB-D63EB05C0D01

P304

Q54218339-5A609F74-613D-4F7A-8FA4-BD76FCBDC976

P31

Q54218339-033FF162-C964-4107-80C7-1079E21CA86F

P356

Q54218339-1A9157C8-64B4-4C6E-AE43-7E423257108D

P433

Q54218339-4E2A0331-82F4-486B-B3F6-9B8386F61BB9

P478

Q54218339-5BFF5BB7-3C6D-4CC0-B052-002B39CBE53B

P50

Q54218339-C23B3311-4DAC-4665-A46B-0C675232D0AE

P577

Q54218339-B5F72E5A-6A48-430F-8DA1-3935CCA3F856

P5875

Q54218339-CA029A41-459A-48F4-B949-0CBFD086272C

P698

Q54218339-4D2B3252-4462-4504-BC8B-B9E9B5C4A4C1

P921

Q54218339-DA9BA421-FBDA-4ADC-9D7C-F6FC59CBF3C4

P356

S10120-014-0360-4

P1433

P1476

Expression profiles of HER2, E ...... s with gastric adenocarcinoma.

@en

P2093

Akiko Kawano Nagatsuma

http://www.w3.org/2001/XMLSchema#string

Atsushi Ochiai

http://www.w3.org/2001/XMLSchema#string

Atsushi Ohtsu

http://www.w3.org/2001/XMLSchema#string

Hirofumi Fujii

http://www.w3.org/2001/XMLSchema#string

Masaki Aizawa

http://www.w3.org/2001/XMLSchema#string

Takeshi Kuwata

http://www.w3.org/2001/XMLSchema#string

P2860

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients.

FGFR2 protein expression in breast cancer: nuclear localisation and correlation with patient genotype.

Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition.

Cancer incidence and incidence rates in Japan in 2006: based on data from 15 population-based cancer registries in the monitoring of cancer incidence in Japan (MCIJ) project.

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.

P2888

s10120-014-0360-4

P304

227-238

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10120-014-0360-4

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-03-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260809899

http://www.w3.org/2001/XMLSchema#string

P698

24626858

http://www.w3.org/2001/XMLSchema#string

P921